Capsazepine is a novel activator of the delta subunit of the human epithelial Na+ channel.
The amiloride-sensitive epithelial Na+ channel (ENaC) regulates Na+ homeostasis into cells and across epithelia. So far, four homologous subunits of mammalian ENaC have been isolated and are denoted as alpha, beta, gamma, and delta. The chemical agents acting on ENaC are, however, largely unknown, except for amiloride and benzamil as ENaC inhibitors. In particular, there are no agonists currently known that are selective for ENaCdelta, which is mainly expressed in the brain. Here we demonstrate that capsazepine, a competitive antagonist for transient receptor potential vanilloid subfamily 1, potentiates the activity of human ENaCdeltabetagamma (hENaCdeltabetagamma) heteromultimer expressed in Xenopus oocytes. The inward currents at a holding potential of -60 mV in hENaCdeltabetagamma-expressing oocytes were markedly enhanced by the application of capsazepine (> or =1 microM), and the capsazepine-induced current was mostly abolished by the addition of 100 microM amiloride. The stimulatory effects of capsazepine on the inward current were concentration-dependent with an EC50 value of 8 microM. Neither the application of other vanilloid compounds (capsaicin, resiniferatoxin, and olvanil) nor a structurally related compound (dopamine) modulated the inward current. Although hENaCdelta homomer was also significantly activated by capsazepine, unexpectedly, capsazepine had no effect on hENaCalpha and caused a slight decrease on the hENaCalphabetagamma current. In conclusion, capsazepine acts on ENaCdelta and acts together with protons. Other vanilloids tested do not have any effect. These findings identify capsazepine as the first known chemical activator of ENaCdelta.
Department of Molecular Morphology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan. yamamura@med.nagoya-cu.ac.jp
Hisao
H
Yamamura
Shinya
S
Ugawa
Takashi
T
Ueda
Masataka
M
Nagao
Shoichi
S
Shimada
D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002211:Capsaicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004224:Diterpenes / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D053503:Epithelial Sodium Channels; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009498:Neurotoxins; D009865:Oocytes / Q000378:metabolism; D017434:Protein Structure, Tertiary; D011522:Protons; D011955:Receptors, Drug / Q000037:antagonists & inhibitors; D015222:Sodium Channels / Q000378:metabolism*; D014981:Xenopus
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004224:Diterpenes; D004232:Diuretics; D053503:Epithelial Sodium Channels; D009498:Neurotoxins; D011522:Protons; D011955:Receptors, Drug; C507051:SCNN1D protein, human; D015222:Sodium Channels; C054256:olvanil; D000584:Amiloride; C024353:resiniferatoxin; C071423:capsazepine; D002211:Capsaicin; D004298:Dopamine